MLchartDataset catalogue

Onatasertib

Term · Oncology and biomedicine · MLC-T-ONC-015623

An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.

Table 1. Record
IdentifierMLC-T-ONC-015623
FieldOncology and biomedicine
SynonymsWHO 11237
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015623",
  "term": "Onatasertib",
  "field": "Oncology and biomedicine",
  "definition": "An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.",
  "synonyms": [
    "WHO 11237"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/onatasertib/"
}

Record 12,174 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.